Zogenix

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.   We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?

New materials were created in collaboration with the Dravet Syndrome Foundation to support and celebrate the brothers and sisters of those living with a rare and severe epilepsy New materials were created in collaboration with the Dravet Syndrome Foundation to support and celebrate the brothers and sisters of those living with a rare and severe epilepsy

Zogenix Introduces New Resources for Dravet Syndrome Siblings

The long-awaited PDUFA date for Zogenix's lead drug, Fintepla® is approaching with the FDA timeline pushback earlier this year offering a favorable entry point into the stock.

Zogenix: Fintepla Late June PDUFA Date - A Catalyzing Moment For Its Shares

Unique tips and tools informed by the Dravet syndrome community are designed to help parents and siblings of a child with Dravet stay positive and connected. Unique tips and tools informed by the Dravet syndrome community are designed to help parents and siblings of a child with Dravet stay positive and connected.

Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet Syndrome

Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2020 Results - Earnings Call Transcript

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Zogenix (ZGNX) This Earnings Season?

New in-house role will lead Zogenix Legal team and serve as a member of the Executive Team New in-house role will lead Zogenix Legal team and serve as a member of the Executive Team

Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary

Zogenix (ZGNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Zogenix (ZGNX) Stock Stands Out in a Strong Industry

Zeroing In On Zogenix

Zogenix's recent slump presents a questionable buying opportunity.

Down 52% in 3 Months, Is This Biotech Stock a Buy?

EMERYVILLE, Calif., March  06, 2020  (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its previously announced underwritten public offering of 9,798,000 shares of its common stock, including 1,278,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, were approximately $230.3 million. 

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., March  03, 2020  (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $200.2 million.  Zogenix has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix. The offering is expected to close on or about March 6, 2020, subject to satisfaction of customary closing conditions.  

Zogenix Prices Public Offering of Common Stock

EMERYVILLE, Calif., March  03, 2020  (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Zogenix.

Zogenix Announces Proposed Public Offering of Common Stock

Zogenix, Inc.'s (ZGNX) CEO Dr.

Shares of Zogenix crumbled to a three-year low Thursday after the biotech company announced a delay for its seizure medicine, Fintepla. The FDA will now review the drug on June 25.

Biotech Stock Crumbles To Three-Year Low On Delayed Seizure Drug

Zogenix May Have Tumbled, But A Buy Opportunity Has Been Created

Zogenix: Buying Opportunity

Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.

Zogenix's Positive Clinical Trial Wasn't Positive Enough

Despite reports of positive late-stage results for an important drug candidate, Wall Street was hoping for more.

Here's Why Zogenix Took a Tumble Today

Zogenix stock plummeted Friday after the biotech company's successful Phase 3 study of an experimental seizure medicine, known as Fintepla, still lagged more bullish expectations.

This Biotech Cratered On Its Good — But Not Good Enough — Test Results

FINTEPLA as adjunctive therapy showed a significant, dose-dependent reduction in convulsive seizure frequency in Dravet syndrome patients versus placebo

The Lancet Publishes Phase 3 Trial Results for Zogenix  Investigational Drug FINTEPLA® in Dravet Syndrome

EMERYVILLE, Calif., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that JAMA Neurology has published the results of Zogenix’s Phase 3 study (Study 1504) of the investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), in Dravet syndrome patients whose antiepileptic drug treatment regimens included stiripentol but who were still experiencing a high number of convulsive seizures. Dravet syndrome is a rare, severe, and very difficult to treat infantile-onset epilepsy characterized by frequent, disabling seizures. The study demonstrated that adding FINTEPLA to these patients’ treatment regimens led to a significant and clinically meaningful (>  50%) reduction in monthly convulsive seizure frequency (MCSF).

JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

Zogenix Inc's (ZGNX) CEO Steve Farr on Q3 2019 Results - Earnings Call Transcript

Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% and -42.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates

EMERYVILLE, Calif., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced positive new data for its investigational drug, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Dravet syndrome. The data were presented in five scientific posters, available  here , at the recent Childhood Neurology Society (CNS) Congress. The posters include data showing long-term, clinically meaningful reduction in convulsive seizure frequency in young Dravet syndrome patients (under 6 years of age) in an ongoing Open-Label Extension (OLE) study, as well as data from a post-hoc analysis showing clinically meaningful and profound reduction in the frequency of high-risk tonic-clonic (grand-mal) seizures in Dravet syndrome patients treated in two previously completed Phase 3 clinical trials. Other data include the results of a Phase 1 study to assess the potential drug-drug interaction of fenfluramine and cannabidiol (CBD).

News for Zogenix Stock (ZGNX)